Sells ARIKAYCE, an inhaled medicine for adults with MAC lung disease, and BRINSUPRI for people with bronchiectasis.
10-K for FY2025, filed Feb 19, 2026
Insmed earns revenue by selling ARIKAYCE and BRINSUPRI; sales count when customers receive the products.
10-K for FY2025, filed Feb 19, 2026
10-K for FY2025, filed Feb 19, 2026
FY2025 revenue by product or service ↗$606.4M
10-K for FY2025, filed Feb 19, 2026
$606.4M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
ARIKAYCE
Sold outright
10-K for FY2025, filed Feb 19, 2026 |
72% |
ARIKAYCE, FY2025
$433.8M Sources
|
Sold outright |
|
BRINSUPRI
Sold outright
10-K for FY2025, filed Feb 19, 2026 |
28% |
BRINSUPRI, FY2025
$172.7M Sources
|
Sold outright |
U.S. buyers include specialty pharmacies and a specialty distributor. ARIKAYCE is sold internationally and in the U.S., while BRINSUPRI sales are in the U.S.
10-K for FY2025, filed Feb 19, 2026Product revenues, net consist of global net sales of ARIKAYCE and US net sales of BRINSUPRI. The Company's customers in the US include…View ↗
No. It lost $1.3B in FY2025.
10-Q for Q3 FY2026, filed Oct 29, 2026
Open tableView ↗
8-K, filed Aug 6, 2026
The Company raised its guidance for full-year 2026 BRINSUPRI revenues to a range of $1.25 billion to $1.40 billion from the previous…View ↗
Growing. Revenue grew 3.2x in 4 years, from $188.5M in FY2021 to $606.4M in FY2025, about 34% a year.
BRINSUPRI becomes a marketed product
BRINSUPRI moved from a development candidate for bronchiectasis to a marketed treatment; the latest report says it was approved in the U.S. and Europe and launched in the U.S.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 19, 2026Our clinical-stage pipeline includes brensocatib, TPIP and early-stage research programs. Brensocatib is a small molecule, oral, reversible…View ↗
Gene therapy candidates advance
The latest report names clinical-stage gene therapy candidates for Duchenne muscular dystrophy and amyotrophic lateral sclerosis, while the older report described gene therapy as an early-stage research modality.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 19, 2026Our clinical-stage pipeline includes brensocatib, TPIP and early-stage research programs. Brensocatib is a small molecule, oral, reversible…View ↗
The clinical-stage programs in our Neuro & Other Rare therapeutic area are INS1201, an intrathecally delivered gene therapy for patients…View ↗
Loading...